Flexion Therapeutics, Inc.reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX 006...
Flexion Therapeutics, Inc. announced that the FDA has informed the company it needs additional time to complete the review of...
Flexion Therapeutics, Inc.announced that the FDA approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection...
Pacira BioSciences, Inc. the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
Flexion Therapeutics announced results from a sensitivity analysis evaluating the treatment effects of a single administration of Zilretta (triamcinolone acetonide...
Flexion Therapeutics, Inc. announced an independent evaluation of clinical data for Zilretta
Flexion Therapeutics announced that the results from an open-label Phase IIIb clinical trial evaluating the safety and exploratory efficacy of...
In this review, we discuss the most recent evidence on mechanisms underlying pathological nociceptive processing in Parkinson's disease patients, as well as novel treatment strategies.
Flexion Therapeutics has reported that the Phase III clinical trial for its lead drug candidate Zilretta (also known as FX006,...